However, the data also shows that once older adults are already engaged with GLP-1 treatment, resistance to tablets drops sharply: 43.19% say pills are more appealing than injections 64.94% of injectable users would consider switching This indicates the primary barrier among older adults may not be the pill format itself, but rather initial adoption of GLP-1 treatment in general
The number on the scale starts to drop
Long-term benefits include cardiovascular risk reduction and potential renoprotective effects in appropriate patients
A racing or irregular heartbeat that lasts, worsens, or comes with dizziness, chest discomfort, or breathlessness
Identification of phytaspase interactors via the proximity-dependent biotin-based identification approach
Metabolically distinct weight loss by 10,12 CLA and caloric restriction highlight the importance of subcutaneous white adipose tissue for glucose homeostasis in mice